系统性硬化症中抗拓扑异构酶I阳性的情境化实验室解读:一项去重真实世界分析
该研究基于单中心2023年队列,按患者最早合格记录及严格住院SSc诊断标准重新分析669例抗拓扑异构酶I LIA灰度值>25的患者。结果显示LIA强度和ANA阳性独立关联SSc记录,联合ANA状态或核型模式可提升AUC;CLIA确认率随LIA强度增加,且ANA阳性者确认率更高。
要点
- 抗拓扑异构酶I阳性需结合ANA状态与LIA强度综合解读。
- ANA阳性者SSc记录率15.7%,显著高于ANA阴性者的0.9%。
- ANA状态、滴度≥1:160及非AC-29模式提供互补实验室信息。
核心结论
- ANA状态、LIA强度、滴度和AC-29模式为抗拓扑异构酶I阳性提供互补的实验室解读情境。
研究设计与样本
- 单中心2023年队列再分析,每例患者取最早合格记录,采用严格记录的住院SSc诊断,共纳入669例LIA灰度值>25的患者。
主要发现
- 669例中ANA阳性440例、ANA阴性229例,SSc记录分别为69/440(15.7%)和2/229(0.9%)。
- LIA强度每增加10单位OR 1.43(95%CI 1.30-1.58),ANA阳性OR 10.57(95%CI 2.51-44.57),均独立关联SSc记录。
- 加入ANA状态使AUC从0.815升至0.847(p=0.011)。
- ANA阳性者中,LIA强度、ANA滴度≥1:160和非AC-29模式独立提供信息,加入模式使AUC从0.817升至0.862(p=0.011)。
- 268例CLIA观察中,确认率随LIA强度增加;未调整确认率ANA阳性为74/122(60.7%),ANA阴性为61/146(41.8%)(p=0.002)。
临床怎么用
- 解读抗拓扑异构酶I阳性时,应同时报告并整合ANA状态、LIA信号强度、ANA滴度及核型模式。
- 对ANA阴性且LIA强度较低者,SSc记录率极低,需谨慎解释阳性结果。
局限性
- 单中心真实世界再分析,仅纳入LIA灰度值>25者,CLIA确认仅限可用子集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess how routinely available serological findings contextualize anti-topoisomerase I positivity in systemic sclerosis (SSc). METHODS: We reanalyzed a single-center 2023 cohort using the earliest qualifying record per patient and strict recorded inpatient SSc diagnoses. Logistic models evaluated antibody signal intensity and antinuclear antibody (ANA) status, titer, and pattern. An available chemiluminescence immunoassay (CLIA) subset provided orthogonal analytical context. RESULTS: Among 669 patients with line-immunoassay (LIA) grayscale values >25 for anti-topoisomerase I, 440 were ANA-positive and 229 ANA-negative; SSc was recorded in 69/440 (15.7 %) and 2/229 (0.9 %), respectively. LIA intensity (per 10 units; OR 1.43, 95 % CI 1.30-1.58) and ANA positivity (OR 10.57, 95 % CI 2.51-44.57) were independently associated with recorded SSc. Adding ANA status increased AUC from 0.815 to 0.847 (p=0.011). Within ANA-positive patients, LIA intensity, ANA titer ≥1:160, and non-AC-29 pattern were independently informative; adding pattern increased AUC from 0.817 to 0.862 (p=0.011). In 268 CLIA observations, confirmation increased with LIA intensity; unadjusted rates were 74/122 (60.7 %) for ANA-positive and 61/146 (41.8 %) for ANA-negative observations (p=0.002). CONCLUSIONS: ANA status, LIA intensity, titer, and AC-29 provide complementary laboratory context for interpreting anti-topoisomerase I positivity.
引用
- Liu, Chen, Song, et al. Contextual laboratory interpretation of anti-topoisomerase I positivity in systemic sclerosis: a de-duplicated real-world analysis. Clin Chem Lab Med. 2026. PMID: 42948942. doi:10.1515/cclm-2026-1461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。